Unlike generic weight loss apps that simply mail pills, we provide a true medical partnership
Bueno M, Calyeca J, Rojas M, Mora AL
Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, MASLD, and other cardio-kidney-metabolic conditions (Diabetes, Obesity & Metabolism)
Because GLP-1 RAs target growing markets (T2DM and obesity affect millions), volume of PA requests has surged
Answer: Good candidates are adults struggling with persistent hunger, a stalled response to GLP-1 medications, insulin resistance, or a long history of weight cycling, who want to address the hormonal driver of appetite rather than rely on restriction alone
Malaguarnera M, Cammalleri L, Fau - Gargante MP, Gargante Mp Fau - Vacante M, Vacante M, Fau - Colonna V, Colonna V, Fau - Motta M, Motta M